The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1313
June 1, 2009
View Complete Issue         Table of Contents 2019 
Bimatoprost 0.03% Solution (Latisse) for Eyelash Enhancement
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Bimatoprost 0.03% Solution (Latisse) for Eyelash Enhancement
June 1, 2009 (Issue: 1313)
The FDA has approved the prostaglandin analog bimatoprost in a 0.03% solution (Latisse - Allergan) for increasing eyelash length, thickness and darkness in patients with hypotrichosis of the eyelashes.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Bimatoprost 0.03% Solution (Latisse) for Eyelash Enhancement
Article code: 1313c
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.